| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0161-6420(85)34036-8 |
| P698 | PubMed publication ID | 2986069 |
| P2093 | author name string | Bay JW | |
| Tomsak RL | |||
| Rogers LR | |||
| Miller DF | |||
| Lederman RJ | |||
| Purvis JD | |||
| P2860 | cites work | Intra-arterial BCNU therapy in the treatment of metastatic brain tumor from lung carcinoma.A preliminary report | Q28328497 |
| Phase II study--intra-arterial BCNU therapy for metastatic brain tumors | Q33476725 | ||
| Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery | Q33483488 | ||
| Current concepts in cancer: brain tumors | Q37969748 | ||
| Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. | Q42256501 | ||
| Limitations of high dose intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas | Q48936235 | ||
| Ocular toxicity associated with high-dose carmustine | Q70505010 | ||
| Supraophthalmic carotid infusion for brain-tumor chemotherapy. Technical note | Q71668922 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 402-406 | |
| P577 | publication date | 1985-03-01 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas | |
| P478 | volume | 92 |
| Q44519740 | Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization Grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Düsseldorf University |
| Q41562477 | DTI-015 produces cures in T9 gliosarcoma |
| Q55485121 | Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. |
| Q30992978 | Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study |
| Q50435642 | Issues in developing drugs for primary brain tumors: barriers and toxicities |
| Q48492798 | Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine |
| Q46328175 | Negative-type electroretinogram from cisplatin toxicity |
| Q44704252 | Ocular and orbital toxicity after intracarotid cisplatin therapy. |
| Q41973401 | Ocular complications after intracarotid BCNU for intracranial tumors |
| Q41137774 | Ocular toxicity and cancer chemotherapy. A review |
| Q35899377 | Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review |
| Q48537424 | Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure |
| Q42223658 | Prevention of ocular toxicity of carmustine (BCNU) with supraophthalmic intracarotid infusion. |
| Q46235710 | Retinal microvessels express less gamma-glutamyl transpeptidase than brain microvessels |
| Q71074380 | Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer |
| Q39615885 | Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer |
| Q34770214 | Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial |
| Q53061845 | The protective effect of selenium in cisplatin-related retinotoxicity. |
| Q37114046 | Toxicology of the retina: advances in understanding the defence mechanisms and pathogenesis of drug- and light-induced retinopathy |
| Q43829843 | Visual toxicity following intra-arterial chemotherapy with hydroxyethyl-CNU in patients with malignant gliomas. A prospective study with statistical analysis |
Search more.